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Background: Metronomic oral vinorelbine could be a safe option for elderly patients with advanced non small cell
lung cancer (NSCLC). Metronomic administration of chemotherapy leads to a cytostatic action shifting treatment
target from cancer cell to tumor angiogenesis.
Methods: 43 chemotherapy naive elderly (≥70 yrs) PS 0-2 patients with stage IIIB-IV NSCLC were prospectively
recruited. Median age was 80 yrs (M/F 36/7) with predominantly squamous histology. PS distribution was
0-1(16)/2(27) with a median of 3 serious co-morbid illnesses. Study treatment consisted of oral vinorelbine 50mg
three times weekly (Monday-Wednesday-Friday) continuously until disease progression, unacceptable toxicity or
patient refusal. Primary endpoints were overall response rate (ORR), clinical benefit (CB – disease response plus
disease stabilization >12 weeks) and safety. Health-related QoL (HRQoL) was also assessed with FACT-L V4 scoring
questionnaire. We conducted an exploratory time-course analysis of VEGF and thrombospondin-1 (TSP1) serum
levels in a subgroup of patients.
Results: Patients received a median of 5 (range 1-21) cycles with a total of 272 cycles delivered. ORR was 18.6%
with 7 partial and 1 complete responses; 17/43 experienced stable disease lasting more than 12 weeks leading to
an overall CB of 58.1%. Median time to progression was 5 (range 2-21) and median overall survival 9 (range 3-29)
months. Treatment was well tolerated with rare serious toxicity. Regardless of severity main toxicities observed were
anemia in 44%, fatigue in 32.4%, and diarrhoea 10.5%. FACT-L v4 scores did not significantly vary during treatment.
Baseline VEGF levels were lower and showed a rapid increase during treatment in non-responders pts only while
TSP1 levels did not change.
Conclusions: Metronomic oral vinorelbine is safe in elderly patients with advanced NSCLC with an interesting
activity mainly consisting in long-term disease stabilization coupled with an optimal patient compliance
(Eudra-CT 2010-018762-23, AIFA OSS on 26 February 2010).
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Non-small cell lung cancer (NSCLC) is the leading cause
of cancer death in Western World [1]. The majority of
diagnosis occurs at an advanced stage and available treat-
ments are still unsatisfactory. More than 50% of cases of
advanced NSCLC are diagnosed in patients older than age
65 years, and approximately 30% to 40% in patients older
than age 70 years [2]. Elderly patients represent an unique
setting in which the risk/benefit ratio of treatment should
be carefully evaluated. They often present with medical
comorbidities and social problems that make the selection
of the optimal treatment quite challenging [3]. Chemo-
therapy with a single agent is an appropriate therapeutic
option suitable for a large number of elderly patients with
advanced NSCLC [4]. Among available drugs, both infu-
sion and oral vinorelbine (VNR) is widely used with a
favorable and foreseeable toxicity profile especially suit-
able for elderly and/or fragile patients [5,6]. Metronomic
chemotherapy (MC) offers the advantage to higher overall
drug dose without worsening safety. It contemplates the
fractionated, frequent and long term administration of
single drug doses without breaks until disease progression
or unacceptable toxicity. MC acts as a cytostatic (non-
cytotoxic) treatment developed to overcome drug resist-
ance by shifting the therapeutic target from tumor cells to
tumor vasculature, thus counteracting tumor regrowth
that may occur between chemotherapy cycles [7]. Oral
metronomic VNR has been tested in three phase I trials
setting 50 mg three times a week (Monday-Wednesday-
Friday) as the reference dose. These trials highlighted the
excellent safety of this schedule and pointed out its activ-
ity [8-10]. Moreover, in the paper by Briasoulis et al. [8]
authors found significant treatment-induced variations in
some endogenous neo-angiogenesis regulators so steering
towards modulation of such pathway to get the anti-
cancer effect.
On these grounds, we conducted the MOVE phase II
trial to explore the role of oral metronomic VNR as




Chemotherapy naive patients aged 70 years or older able
to take oral medications with hystologically or cytologic-
ally confirmed, stage IIIB (not suitable for surgery and
chemo-radiotherapy) or IV NSCLC according to UICC-
TNM 7th edition with RECIST 1.1 measurable disease
were eligible for the study. Additional entry criteria
included ECOG PS 0–2, a life expectancy of at least
3 months, adequate bone marrow reserve and adequate
hepatic and renal function. We excluded patients with
previous (within 5 years) or concomitant malignancies,
symptomatic brain metastases and activating epidermalgrowth factor receptor (EGFR) mutations. Concomitant
radiotherapy was not allowed. Written informed consent
was obtained before study entry and study procedures
were in accordance with Helsinki Declaration. This trial
received approval by local Ethical Committee (Comitato
Etico AUSl 12 di Viareggio) and was registered with
Eudra-CT n° 2010-018762-23 and appears on Agenzia
Italiana del Farmaco (AIFA) observatory on February 26th
2010. Baseline evaluation included medical history, phys-
ical examination, symptom assessment, PS determination,
complete blood cell count and serum chemistry. Baseline
staging consisted computed tomography (CT) scan of the
thorax and upper abdomen. Brain CT and bone scan were
reserved to symptomatic patients. Health-related quality
of life (HRQoL) was assessed at baseline, during treatment
and at study-end by mean of the Italian version of FACT-L
v4 questionnaire. We consider the following as serious
co-morbid illnesses: Heart disease (previous myocardial
infarction, heart failure, valvular heart disease and serious
arrhythmias), chronic obstructive pulmonary disease
(COPD), diabetes, cerebral or peripheral vascular disease,
chronic renal failure, hepatitis and/or cirrosis, hypertension
and severe auto-immune diseases.
Study design and treatment
Oral vinorelbine was administered at the dose of 50 mg
(one capsule of 20 mg plus one of 30 mg) three times
weekly on Monday, Wednesday and Friday continuously
until disease progression, patient refusal or excessive tox-
icity. Vinorelbine capsules were taken after a meal without
chewing or sucking the capsules. No primary prophylaxis
with antiemetics was recommended but delivered upon
request. In case of diarrhoea loperamide was recom-
mended. Granulocyte colony-stimulating factors were
allowed in grade 3 neutropenia with fever lasting ≥3 days
or in case of grade 4 neutropenia. The use of erythropoi-
etin was allowed. We consider three weeks as a cycle.
Patients took treatment at home. Patients were seen every
cycle and complete blood cell count and serum chemistry
were performed. Dose adjustment was made as follow: if
grade 3/4 hematologic or non-hematologic toxicity or
persistent grade 2 toxicity with impact on daily activities
occurred at any time during cycle, dose was reduced to
30 mg three times weekly at first occurrence and to 20 mg
three times weekly at second occurrence. If grade 3/4
toxicity still occurs treatment was permanently stopped.
Patients received any other palliative treatment needed.
Disease assessment and study objectives
Disease evaluation was performed with chest/upper
abdomen CT every nine weeks during treatment. During
follow-up disease evaluation was performed every three
months. Primary end-points were response rate (RR)
(according to RECIST 1.1 criteria), clinical benefit (CB –
Table 1 Baseline study population characteristics (n = 43)
Age (yrs)
median (range) 80 (70 – 92)
Sex (M/F) 36/7




median (range) 3 (0 – 6)
Histology (n/%)
Squamous cell carcinoma 24/43 (55.8%)
Adenocarcinoma 11/43 (25.6%)
Large-cell carcinoma 4/43 (9.3%)
Undifferentiated 4/43 (9.3%)
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12 weeks) and safety. Secondary end-points were time to
progression (TTP), overall survival (OS) and HRQoL.
Complete and partial responses were defined according
to RECIST 1.1. TTP was calculated from the date of
treatment start to the date of first-documented progres-
sion or patient death. OS was defined as the time inter-
val between the start of study treatment and death or
last follow-up contact. Adverse events were recorded
according to the CTCAE v3.0.
Exploratory VEGF and thrombospondin-1 analysis
Patients who agreed to optional exploratory substudy were
required to sign a separate additional informed consent.
Peripheral venous blood samples were taken at baseline,
every 3 weeks for the first 3 months and then at disease
progression. Serum samples were stored at −20°. Vascular
endothelial growth factor (VEGF) and thrombospondin-1
(THS1) concentrations were determined using ELISA
commercially available kits. Protocols, procedures, and
equipment were used according to the manufacturer's
specifications. VEGF levels were expressed in pg/ml and
TSP1 in ng/ml. Analysis were carried out in duplicate.
Exceeded serum was destroied.
Statistical methods
Given a low-interest response rate (P0) of 10% and a
treatment-related response rate of clinical interest (P1)
of 25%, an α-error of 0.05 and β-error of 0.2, according
to Simon’s Minimax design for two-step phase II trial we
aimed to enroll 18 pts at first step. In case of treatment
responses >2 the enrolment continued to a total of 43 pts.
Study treatment can be considered of clinical interest in
case of a total treatment responses >7. Trial accrual
started on march 2010 and ended on July 2013. All data
were analyzed at a cut-off date of January 2014 represent-
ing the disease progression time (and so the end of active
treatment) of last study patient. At report time overall sur-
vival data are available for all patients. Survival parameters
(TTP and OS) were expressed as median and range. In
the exploratory VEGF and TSP1 serum level analysis,
values were expressed as mean ± standard deviation of




First-step results were available October 2011. We ob-
served 3 treatment responses with a good safety profile
so we kept on enrolment until a total of 43 patients.
Baseline study population characteristics are shown in
Table 1. Median age was 80 [range 70–92] years. Sex
distribution showed a clear predominance of males (M/F
36/7) with squamous cell-histology tumors being themost represented (24/43). ECOG PS 2 patients repre-
sented the 62.8% (27 out of 43) of the whole population
with a median of 3 [range 0–6] serious co-morbid
illnesses. Most frequent co-morbid illnesses were COPD
(63%), heart disease (38%) and diabetes (21%).
Drug administration
A total of 272 cycles were given with a median number
of cycles of 5 (range 1–21). All patients received at least
1 cycle with 55.8% (24/43) that received at least 5 cycles.
One-step dose reduction to 30 mg three times weekly
occurred in 7 patients (in all cases after 3 cycles) due to
fatigue in 3 patients, nausea in 1 patient and to diar-
rhoea in 3 patients. Only one patient required two-step
dose reduction to 20 mg three times weekly due to grade
3 diarrhoea. After dose reduction the patients did not
experience any further significant toxicity. Dose delay of
few days occurred in 5 patients for a total of 10 cycles
and it was not related to grade 3/4 toxicity but to patient
personal preferences. Treatment compliance was high.
Efficacy
All patients received at least 1 treatment cycle and, at
report time, all of them experienced disease progression
and were consequently evaluable for both efficacy and
safety analysis. Four patients are still alive. We observed
7 partial responses and one complete response in a
patient with bilateral lung disease resulting in an overall
RR of 18.6%. Moreover, 17/43 (39.5%) showed disease
stability lasting more than 12 weeks with a global CB of
58.1% (Table 2). Survival analysis demonstrated a
median TTP of 5 (range 2–21) and an OS of 9 (range
3–29) months (Table 2). The percentage of alive patients
at one year was 37.2% (16 out of 43) with 4 patients alive
at two years. The final RR of 18.6% (8 out of 43 patients)
met the default clinical interest threshold. Interestingly,
Table 2 Clinical efficacy data at final analysis on 43 patients
Number of cycles (median - range) 5 [1 - 21]
Treatment response (n - %)
CR 1/43 – 2.3%
PR 7/43 - 16.3%
SD 17/43 - 39.5%
PD 18/43 - 41.9%
Clinical benefit 25/43 - 58.1%
ORR 8/43 - 18.6%
TTP (median - range) 5 [2 - 21] months
OS (median - range) 9 [3 - 29] months
Percentage of alive patients (n - %)
year 1 16/43 - 37.2%
year 2 4/43 - 9.3%
CR = complete response; PR = partial response; SD = stable disease;
PD = disease progression; ORR = overall response rate; TTP = time to
progression; OS = overall survival.
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treatment and 4 out of 43 (9.3%) a third-line one.
Toxicity and quality of life
Study treatment was extremely safe. Grade (G) 3/4
toxicities were rare (two episodes of G3 diarrhoea, one
of not-febrile G3 neutropenia, one G3 mucositis, one G3
anemia and two G3 fatigue on a total of 272 cycles deliv-
ered). Regardless of severity main toxicities observed
were anemia in 44%, fatigue in 32.4%, diarrhoea 10.5%,
nausea 8%, vomiting 5% (Table 3). There was no
treatment-related death and none of the study patients
required hospitalization for treatment-related adverse
events. Moreover, during treatment no patient required
blood or platelet transfusions or intravenous antibiotics
and granulocyte colony-stimulating factors were notTable 3 All grade (left column) and grade 3/4 (right column)
treatment-related toxicities at final analysis (n = 43)












*Rounded to 0.1%.used. Only the patient that experienced grade 3 not-
febrile neutropenia received oral antibiotics prophylaxis
for 5 days. FACT-L v4 scores did not significantly vary
during treatment.
VEGF and thrombospondin-1 analysis
Serum levels of VEGF and TSP1 were assessed in 28 pa-
tients. Baseline VEGF levels significantly differ between non-
responders (n = 12) vs responders (including SD >12 weeks)
patients (n = 16) (303.8 ± 128.6 vs 660.9 ± 280.4 pg/ml;
p = 0.04). Time course analysis did not show any signifi-
cant change in VEGF levels in whole population or in
responders patients while in non-responders group
(n = 12) we observed a clear increase during treatment
until early disease progression (303.8 ± 128.6 vs 579.3 ±
181.2 vs 498.0 ± 211.6 vs 633.4 ± 151.8 pg/ml; p = 0.02)
(Figure 1). No difference in baseline levels between pa-
tients groups or in time course variation were observed
for TSP1 levels.
Discussion
The selection of optimal systemic treatment for elderly
patients with advanced NSCLC should rely on both per-
sonal (including PS, comorbidities, polypharmacy) and
surrounding (familial and social features ) issues making
treatment choice as an hard challenge [3]. The best
treatment for elderly patients or those with low PS is
still debated with single agent chemotherapy being one
of the preferred options to treat these patients [11].
Oral vinorelbine could be an attractive option. In fact,
with the assumption of an equal efficacy, patients
expressed a preference for oral over intravenous chemo-
therapy [12,13] and the oral formulation could potentially
lesser nearly half of the major patient concerns about
chemotherapy [14,15].
Our results showed that single agent metronomic oral
vinorelbine is a feasible option as first-line treatment in
elderly patients with advanced NSCLC. Safety issues are
of primary importance in this setting We observed rareFigure 1 Time course variation in VEGF serum levels in non-responders
patients (n = 12).
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erated (Table 3). On a total of 272 cycles administered
we did not observe any grade 4 toxicity; we only ob-
served two episodes of G3 diarrhoea, one of not-febrile
G3 neutropenia, one G3 mucositis, one G3 anemia and
two G3 fatigue with and acceptable rate of low grade
both hematological and not-hematological toxicities
never interfering with treatment, patient dietary intake,
daily life or non-study drug administration and without
any treatment-related death or hospitalization. Patients
did not report any worsening of their QoL scores.
Coupled with the excellent toxicity profile we observed
an interesting activity of oral metronomic vinorelbine
with an overall RR of 18.6% with 7 partial and one
complete responses and a global CB of 58.1%. Survival
data were also encouraging with a median TTP of 5 and
a median OS of 9 months. Notably, study population is
made of "real" elderly patients with a median age of
80 years, a significant number of serious comorbidities
and a low PS in more than half of cases.
MILES trial [16] showed that first-line single agent
vinorelbine or gemcitabine resulted in an OS ranging
from 28 to 36 weeks with a TTP of 17–18 weeks. Previ-
ous ELVIS trial [5] demonstrated an absolute survival
advantage of vinorelbine plus best supportive care (BSC)
over BSC alone with an OS of 28 weeks. In both trials
mean age was 74 years with a percentage of PS 2 pa-
tients less than 25%. Characteristics of our population
are quite different with a median age of 80 years and a
proportion of PS 2 patients more than 50%. Oral vino-
relbine has been also tested with weekly schedules in 56
chemo-naive NSCLC elderly patients. Grade 3/4 neutro-
penia was reported in 11/17 out of 56 patients (20/30%
of total population respectively) with only 1 febrile neu-
tropenia. Six partial responses and 25 SD were recorded
with a median overall survival of 8.2 months [17]. For
discussion purposes only, it could be of interest to com-
pare our results with those of the aforementioned ELVIS,
MILES (single agent vinorelbine arm) and Gridelli et al.
[17] trials in terms of final outcome (approximating OS
in weeks). Bearing in mind the different populations, OS
was similar (36, 28, 36, 33 and weeks respectively) thus
confirming activity of metronomic schedule in real
world elderly patients.
In last few years new data on the role of doublet plat-
inum based chemotherapy in elderly advanced NSCLC
has emerged. Quoix et al. [18] reported a survival advan-
tage of the carboplatin and paclitaxel doublet versus
monotherapy (gemcitabine or vinorelbine). Study popula-
tion is still different from our with a percentage of PS 2
patient of 27% and a median age of 77; no mention about
number of serious comorbid illnesses was reported. Not-
ably, doublet arm was affected by a three-fold increase in
toxic deaths and a similar increase in febrile neutropeniaand decrease in neutrophil count. Our results cannot be
directly compared with French experience. Target popula-
tion of our study is different from Quoix study. Basically,
all study patients were considered eligible to receive plat-
inum as entry criteria while ours did not due to older age,
serious comorbidities and low PS. So, as a possible state-
ment, if a patient is deemed fit to platinum doublet he
should receive it but, if not, single agent metronomic oral
vinorelbine can be an active option. Oral weekly vinorel-
bine has been widely used in the treatment of NSCLC
[19] with a good safety profile. Our data seem to indicate
that its metronomic administration can lead to a gain in
activity without worsening safety profile. Notably, with the
proposed schedule we higher the cumulative dose and,
given the dose-effect relationship, we can so suppose to
obtain a gain in efficacy. In contrast, delivering such an
increased cumulative dose did not affect safety disproving
the dose-toxicity relationship. Metronomic administration
could so allow us to give an active treatment even in frail
patients but still judged suitable for a treatment.
Subgroup analysis of VEGF serum levels gave us some
interesting hints. Not-responders patients showed a low
baseline VEGF levels respect to responder ones in contrast
with Briasuolis et al. [8]. Interestingly, in not-responder
patients we observed a rapid increased in VEGF levels
kept until disease progression while in responder-ones
VEGF levels resulted unchanged. Given the cytostatic/
non-cytotoxic action of metronomic treatment interfering
with cancer neo-angiogenesis processes [7] we can suppose
that in responder patients study treatment can effectively
stop tumor growth by limiting neo-angiogenesis and so we
do not observe any VEGF level increase. In not-responder
ones treatment is uneffective, newly formed endothelial
tumor cells spread and we observe an increased VEGF
levels contributing to a rapid disease progression.
Conclusions
This is the first trial testing metronomic schedule in a se-
lected population of elderly advanced NSCLC patients.
Our results highlighted the safety of metronomic oral
vinorelbine in real world setting of elderly patients with an
interesting activity and favourable QOL data. Oral metro-
nomic vinorelbine could so represent a treatment option
in elderly patient unfit for a platinum doublet but still suit-
able for an active treatment.
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